

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: <u>June 16, 2010</u> (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	1	of	2	Application Number	10/507,060
				Filing Date	06/13/2005
				First Named Inventor	Rolf Baenteli
				Art Unit	1624
				Examiner Name	Deepak R RAO
				Attorney Docket Number	999100-0102

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
	A1	US 2006/0247241 A1	11-02-2006	GARCIA-ECHEVERRIA ET AL	
	A2	US 3,361,749	01-02-1968	MATTER ET AL	
	A3	US 6,093,716 A	07-25-2000	DAVIS ET AL	
	A4	US 6,114,333 A	09-05-2000	DAVIS ET AL	
	A5	US 6,593,326 B1	07-15-2003	BRADBURY ET AL	
	A6	US 7,671,063 B2	03-02-2010	BAENTELI ET AL	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		
	A7	WO 01/64654 A1	09-07-2001	ASTRAZENECA AB	
	A8	WO 03/030909 A1	04-17-2003	BAYER CORP	
	A9	WO 03/063794 A2	08-07-2003	RIGEL PHARMACEUTICALS INC	
	A10	WO 03/066601 A1	08-14-2003	SMITHKLINE BEECHAM CORP	
	A11	WO 03/078404 A1	09-25-2003	NOVARTIS PHARMA GMBH	
	A12	WO 03/095448 A1	11-20-2003	BAYER PHARMACEUTICALS CORP	
	A13	WO 2004/002964 A1	01-08-2004	YAMANOUCHI PHARMACEUTICAL CO LTD	ABS
	A14	WO 2004/056786 A2	07-08-2004	PFIZER PRODUCTS INC	
	A15	WO 2004/074244 A2	09-02-2004	SMITHKLINE BEECHAM CORP	
	A16	WO 2004/080980 A1	09-23-2004	NOVARTIS AG	
	A17	WO 2005/016894 A1	02-24-2005	NOVARTIS PHARMA GMBH	
	A18	WO 2005/026130 A1	03-24-2005	NOVARTIS PHARMA GMBH	
	A19	WO 2006/068770 A1	06-29-2006	RIGEL PHARMACEUTICALS INC	
	A20	WO 99/50250 A1	10-07-1999	JANSSEN PHARMACEUTICA NV	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

Examiner Signature	/Deepak Rao/	Date Considered	08/02/2010
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Application Number</b>	10/507,060	
Date Submitted: <u>June 16, 2010</u>			<b>Filing Date</b>	06/13/2005	
(use as many sheets as necessary)			<b>First Named Inventor</b>	Rolf Baenteli	
Sheet	2	of	2	<b>Art Unit</b>	1624
				<b>Examiner Name</b>	Deepak R RAO
				Attorney Docket Number	999100-0102

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
A21		WOOD ET AL., "PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration", CANCER RES., Vol. 60 (2000), pgs. 2178-2189			
A22		VAN SEVENTER ET AL., "Focal adhesion kinase regulates $\beta_1$ , integrin-dependent T Cell migration through an HEF1 effector pathway", Eur. J. Immunol., Vol. 31 (2001), pgs. 1417-1427			
A23		COOPMAN ET AL., "The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells", Nature, Vol. 406 (2000), pgs. 742-747			
A24		DIRKS ET AL., "Expression and Functional Analysis of the Anaplastic Lymphoma Kinase (ALK) Gene in Tumor Cell Lines", Int. J. Cancer, Vol. 100 (2002), pgs. 49-56			
A25		GHONEIM ET AL., "Synthesis and Evaluation of some 2-, 4- and 2, 4-Di-substituted-6-methylpyrimidine Derivatives for Antimicrobial Activity", J. Indian Chem. Soc., Vol. 63, No. 10 (1986), pgs. 914-917			
A26		DOLLY GHOSH, "2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents", J. Indian Chem. Soc., Vol. 58, No. 5 (1981), pgs. 512-513			
A27		GOSH ET AL., "2,4-Bis(arylamino)-5-methylpyrimidines as Antimicrobial Agents", Journal of Medicinal Chemistry, Vol. 10, No. 5 (1967), pg. 974			
A28		ROLF BAENTELI, U.S. PTO Notice of Allowance, Serial No. 11/377,716, 10-13-2009, 7 pgs.			
A29		ROLF BAENTELI, U.S. PTO Office Action, Serial No. 11/377,716, 06-01-2009, 16 pgs.			
A30		ROLF BAENTELI, U.S. PTO Office Action, Serial No. 11/377,716, 12-12-2008, 21 pgs.			
A31		CARLOS GARCIA-ECHEVERRIA, U.S. PTO Office Action, Serial No. 10/549,250, 01-28-2009, 24 pgs.			
A32		CARLOS GARCIA-ECHEVERRIA, U.S. PTO Office Action, Serial No. 10/549,250, 05-20-2010, 11 pgs.			
A33		CARLOS GARCIA-ECHEVERRIA, U.S. PTO Office Action, Serial No. 10/549,250, 11-12-2009, 15 pgs.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

Examiner Signature	/Deepak Rao/	Date Considered	08/02/2010
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the law to be) provided by an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.